Please assess the completion status of the following clinical trial:

Trial Title: A Study of PF-06873600 in People With Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer~  • Prior combined CDK 4/6 inhibitor and endocrine therapy and 1 or 2 prior lines of chemotherapy~* Have a diagnosis of metastatic triple negative breast cancer (TNBC)~  • Up to 1-2 prior lines of chemotherapy~* Have a diagnosis of advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC)~  • Up to 2-3 prior lines of therapy~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1~* Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)~* Measurable disease as defined by RECIST 1.1 is required (Part 1B and Part 2 only)~Exclusion Criteria:~* Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases~* Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ~* Major surgery or radiation within 4 weeks prior to study entry~* Last anti-cancer treatment within 2 weeks prior to study entry~* Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry~* Pregnant or breastfeeding female patients~* Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastro intestinal function or GI disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation (Type: EXPERIMENTAL): Single Agent Dose Escalation
- Dose Finding Endocrine Therapy 1 Combination (Type: EXPERIMENTAL): Part 1B PF-06873600 plus Endocrine Therapy 1
- Dose Finding Endocrine Therapy 2 Combination (Type: EXPERIMENTAL): Part 1B PF-06873600 plus Endocrine Therapy 2
- Dose Expansion Arm A (Type: EXPERIMENTAL): PF-06873600 as a Single Agent
- Dose Expansion Arm B (Type: EXPERIMENTAL): PF-06873600 as a Single Agent in Various Tumor Types
- Dose Expansion Arm C (Type: EXPERIMENTAL): PF-06873600 in Combination with Endocrine Therapy 1
- Dose Expansion Arm D (Type: EXPERIMENTAL): PF-06873600 in Combination with Endocrine Therapy 1
- Dose Expansion Arm E (Type: EXPERIMENTAL): PF-06873600 in Combination with Endocrine Therapy 2

Based on this trial design, predict the completion outcome and termination type (if applicable).